Kalaris Therapeutics, Inc.
KLRS Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.86
KIRA · Stoqly’s AI analyst, in plain words
- Kalaris Therapeutics, Inc. lost $43.4M in fiscal 2025.
- Free cash flow was −$38.6M in fiscal 2025, — of revenue.
Market cap
$44.3M
P/E
—
Revenue
—
Net income
−$43.4M
Free cash flow
−$38.6M
Operating margin
—
Kalaris Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$43.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kalaris Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 17, 2026
- Legal name
- Kalaris Therapeutics, Inc.
- CIK
- 0001754068
Kalaris Therapeutics, Inc. · KLRS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$172M | −$169M | −$190M | −$69.2M | −$43.4M |
| Diluted EPS | −$2.74 | −$2.20 | −$42.09 | −$51.77 | −$2.85 |
| Cash | |||||
| Cash from operations | −$106M | −$142M | −$124M | −$20.7M | −$38.4M |
| Capital expenditure | $0.0M | — | — | — | $0.2M |
| Free cash flow | −$106M | — | — | — | −$38.6M |
| Share count change | 133.4% | 22.1% | −94.1% | −70.5% | 1,042.9% |
| Debt and strength | |||||
| Cash and short-term investments | $248M | $234M | $184M | $1.6M | $118M |
| Shareholders' equity | $225M | $225M | −$45.0M | −$96.6M | $78.8M |
| Current ratio | 6.7x | 10.0x | 6.6x | 0.1x | 12.2x |
| Interest coverage | — | — | — | −19.2x | −32.0x |
| Returns and quality | |||||
| Return on equity | −59.5% | −75.0% | −212.2% | — | — |
| Return on tangible equity | −76.3% | −75.1% | — | — | −55.1% |
| Altman Z'' | 1.4 | 0.0 | −13.8 | −143.4 | 1.0 |
Insiders bought, 12 months
$6.2M
2 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kalaris Therapeutics, Inc. · KLRS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.86 a share, the company is worth $44.3M.
Source: SEC EDGAR XBRL filings (CIK 0001754068). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.